The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review

被引:5
作者
Zhu, Ke [1 ]
Tian, Yuke [2 ]
Dong, Xiaomei [1 ]
Akinwunmi, Babatunde O. [3 ]
Zhang, Casper J. P. [4 ]
Huang, Jian [5 ]
Ming, Wai-kit [1 ,6 ]
机构
[1] Jinan Univ, Sch Med, Dept Publ Hlth & Prevent Med, Guangzhou, Peoples R China
[2] Univ Elect Sci & Technol China, Dept Med Oncol, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China
[3] Harvard Med Sch, Dept Obstet & Gynecol, Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Univ Hong Kong, Sch Publ Hlth, LSK Fac Med, Hong Kong, Peoples R China
[5] ASTAR, Singapore Inst Clin Sci SICS, Singapore, Singapore
[6] City Univ Hong Kong, Dept Infect Dis & Publ Hlth, Jockey Club Coll Vet Med & Life Sci, Hong Kong, Peoples R China
关键词
Cost-effectiveness; HPV vaccination; Asia; Systematic review; HUMAN-PAPILLOMAVIRUS VACCINATION; ECONOMIC-EVALUATION; NATURAL-HISTORY; CERVICAL-CANCER; IMPACT; INFECTION; TRANSMISSION; LEVEL; WOMEN;
D O I
10.1007/s00404-021-06309-y
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose The aim of this study was to systematically review the cost-effectiveness of HPV vaccination in Asia. Methods We performed a systematic review of papers indexed in PubMed, Scopus, and Web of Science covering the period from 1 January 2000 to 13 August 2020. Results Sixteen studies were included in the review. Half of them (8 studies) evaluated the cost-effectiveness of HPV vaccination in high-income countries and regions (HICs) while the other eight studies were set in low- and middle-income countries and regions (LMICs). In HICs, the implementation of bivalent, quadrivalent and nine-valent HPV vaccination was all shown to be cost-effective. Most studies (7/8) also showed that it was cost-effective to implement bivalent, quadrivalent, and nine-valent HPV vaccines in LMICs. However, one study concluded that it was not cost-effective to implement bivalent HPV vaccination in Thailand. Conclusion In general, the implementation of bivalent, quadrivalent and nine-valent HPV vaccination for adolescent girls was cost-effective in both high-income countries and regions and low- and middle-income countries and regions in Asia. Policy makers in HICs could consider expanding the target vaccinated population, while for LMICs it is essential to reduce HPV vaccine price to a level at which the implementation of HPV vaccination is cost-effective.
引用
收藏
页码:173 / 187
页数:15
相关论文
共 38 条
  • [1] [Anonymous], 2017, Wkly Epidemiol Rec, V92, P241
  • [2] [Anonymous], THE NEWSROOM
  • [3] Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan
    Anwari, Palwasha
    Debellut, Frederic
    Vodicka, Elisabeth
    Clark, Andrew
    Farewar, Farhad
    Zhwak, Zubiada A.
    Nazary, Dastagger
    Pecenka, Clint
    LaMontagne, D. Scott
    Safi, Najibullah
    [J]. VACCINE, 2020, 38 (06) : 1352 - 1362
  • [4] The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
    Brown, Darron R.
    Kjaer, Susanne K.
    Sigurdsson, Kristjan
    Iversen, Ole-Erik
    Hernandez-Avila, Mauricio
    Wheeler, Cosette M.
    Perez, Gonzalo
    Koutsky, Laura A.
    Tay, Eng Hseon
    Garcia, Patricia
    Ault, Kevin A.
    Garland, Suzanne M.
    Leodolter, Sepp
    Olsson, Sven-Eric
    Tang, Grace W. K.
    Ferris, Daron G.
    Paavonen, Jorma
    Steben, Marc
    Bosch, F. Xavier
    Dillner, Joakim
    Joura, Elmar A.
    Kurman, Robert J.
    Majewski, Slawomir
    Munoz, Nubia
    Myers, Evan R.
    Villa, Luisa L.
    Taddeo, Frank J.
    Roberts, Christine
    Tadesse, Amha
    Bryan, Janine
    Lupinacci, Lisa C.
    Giacoletti, Katherine E. D.
    Sings, Heather L.
    James, Margaret
    Hesley, Teresa M.
    Barra, Eliav
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07) : 926 - 935
  • [5] Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis
    Bruni, Laia
    Diaz, Mireia
    Barrionuevo-Rosas, Leslie
    Herrero, Rolando
    Bray, Freddie
    Xavier Bosch, F.
    de Sanjose, Silvia
    Castellsague, Xavier
    [J]. LANCET GLOBAL HEALTH, 2016, 4 (07): : E453 - E463
  • [6] Natural history and epidemiology of HPV infection and cervical cancer
    Castellsague, Xavier
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 110 (03) : S4 - S7
  • [7] The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach
    Chanthavilay, Phetsavanh
    Reinharz, Daniel
    Mayxay, Mayfong
    Phongsavan, Keokedthong
    Marsden, Donald E.
    Moore, Lynne
    White, Lisa J.
    [J]. BMC HEALTH SERVICES RESEARCH, 2016, 16
  • [8] Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan
    Connelly, Luke B.
    Le, Ha N. D.
    [J]. SEXUAL HEALTH, 2015, 12 (06) : 520 - 531
  • [9] Modeling optimal cervical cancer prevention strategies in Nigeria
    Demarteau, Nadia
    Morhason-Bello, Imran O.
    Akinwunmi, Babatunde
    Adewole, Isaac F.
    [J]. BMC CANCER, 2014, 14
  • [10] HPV vaccines to prevent cervical cancer and genital warts: an update
    Dochez, Carine
    Bogers, Johannes J.
    Verhelst, Rita
    Rees, Helen
    [J]. VACCINE, 2014, 32 (14) : 1595 - 1601